The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Prognostic value of baseline immune suppressive biomarkers to select non-small cell lung cancer (NSCLC) patients (pts) likely to benefit from the plinabulin/docetaxel (Plin/Doc) combination. This is ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
By activating the EGF/EGFR signaling pathway and downstream cascades, such as Src/PI3K/Akt/mTOR, it may be possible to enhance the motility and proliferative capacity of oral keratinocytes during ex ...
DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback